Pomalidomide
- Generic Name
- Pomalidomide
- Brand Names
- Imnovid, Pomalyst, Imnovid (previously Pomalidomide Celgene), Pomalidomide Viatris, Pomalidomide Zentiva, Pomalidomide Krka, Pomalidomide Accord
- Drug Type
- Small Molecule
- Chemical Formula
- C13H11N3O4
- CAS Number
- 19171-19-8
- Unique Ingredient Identifier
- D2UX06XLB5
- Background
Pomalidomide, an analogue of thalidomide, is an immunomodulatory antineoplastic agent. FDA approved on February 8, 2013.
- Indication
Pomalidomide is indicated for patients with multiple myeloma who have received at least two prior therapies including lenalidomide and have demonstrated disease progression on or within 60 days of completion of the last therapy. It is also indicated for the treatment of Kaposi's sarcoma (KS) in AIDS patients who have failed highly active antiretroviral thera...
- Associated Conditions
- Kaposi's Sarcoma, Multiple Myeloma (MM)
- Associated Therapies
- -
Pomalidomide After Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
- Conditions
- Interventions
- First Posted Date
- 2014-01-08
- Last Posted Date
- 2020-10-14
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 50
- Registration Number
- NCT02029950
- Locations
- 🇺🇸
Yale University, New Haven, Connecticut, United States
🇺🇸UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States
🇺🇸Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States
Japanese Phase 2 Study to Evaluate the Efficacy and Safety of Pomalidomide in Subjects With Relapsed and Refractory Multiple Myeloma
- First Posted Date
- 2013-12-13
- Last Posted Date
- 2016-11-01
- Lead Sponsor
- Celgene Corporation
- Target Recruit Count
- 36
- Registration Number
- NCT02011113
- Locations
- 🇯🇵
Celgene Trial Site, Tokyo, Japan
Pomalidomide and Dexamethasone With or Without Ixazomib in Treating Patients With Relapsed Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2013-12-09
- Last Posted Date
- 2023-12-01
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 118
- Registration Number
- NCT02004275
- Locations
- 🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
🇺🇸Riverside Methodist Hospital, Columbus, Ohio, United States
🇺🇸NorthShore University HealthSystem-Glenbrook Hospital, Glenview, Illinois, United States
A Study of Oprozomib, Pomalidomide, and Dexamethasone in Adults With Primary Refractory or Relapsed and Refractory Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2013-12-03
- Last Posted Date
- 2021-04-27
- Lead Sponsor
- Amgen
- Target Recruit Count
- 33
- Registration Number
- NCT01999335
- Locations
- 🇺🇸
Duke University Medical Center, Durham, North Carolina, United States
🇺🇸James R. Berenson, MD, Inc., West Hollywood, California, United States
🇺🇸Innovative Clinical Research Institute, Whittier, California, United States
A Study of JNJ-54767414 (HuMax CD38) (Anti-CD38 Monoclonal Antibody) in Combination With Backbone Treatments for the Treatment of Patients With Multiple Myeloma
- First Posted Date
- 2013-12-03
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 240
- Registration Number
- NCT01998971
A Phase 1 QT Study in Healthy Male Subjects
- Conditions
- Interventions
- First Posted Date
- 2013-11-19
- Last Posted Date
- 2019-11-12
- Lead Sponsor
- Celgene
- Target Recruit Count
- 72
- Registration Number
- NCT01986894
- Locations
- 🇺🇸
PPD Phase I Clinic, Austin, Texas, United States
Study of Pomalidomide, Dexamethasone, and Romidepsin for Rel/Ref Myeloma
- Conditions
- Interventions
- First Posted Date
- 2013-11-08
- Last Posted Date
- 2018-06-06
- Lead Sponsor
- Weill Medical College of Cornell University
- Target Recruit Count
- 4
- Registration Number
- NCT01979276
- Locations
- 🇺🇸
Weill Cornell Medical College, New York, New York, United States
Pomalidomide, Dexamethasone, and Filgrastim-sndz in Treating Patients With Relapsed or Refractory Multiple Myeloma
- First Posted Date
- 2013-09-19
- Last Posted Date
- 2021-07-30
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 21
- Registration Number
- NCT01946152
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Pomalidomide in Combination With Low-dose Dexamethasone or Pomalidomide in Combination With Low-dose Dexamethasone and Daratumumab in Subjects With Relapsed or Refractory Multiple Myeloma Following Lenalidomide-based Therapy in the First or Second Line Setting
- Conditions
- Interventions
- First Posted Date
- 2013-09-19
- Last Posted Date
- 2023-05-16
- Lead Sponsor
- Celgene
- Target Recruit Count
- 186
- Registration Number
- NCT01946477
- Locations
- 🇺🇸
Local Institution - 109, Los Angeles, California, United States
🇺🇸Local Institution - 101, Hackensack, New Jersey, United States
🇺🇸CR Wood Cancer Center, Glens Falls, New York, United States
Study to Evaluate Pharmacokinetics of Pomalidomide in Hepatically Impaired Males
- Conditions
- Interventions
- First Posted Date
- 2013-04-19
- Last Posted Date
- 2019-11-12
- Lead Sponsor
- Celgene
- Target Recruit Count
- 32
- Registration Number
- NCT01835561
- Locations
- 🇺🇸
Orlando Clinical Research Center, Orlando, Florida, United States
🇺🇸DaVita Clinical Research, Minneapolis, Minnesota, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.